Muhammad Furqan, Taher Abu-Hejleh, Laura M Stephens, Stacey M Hartwig, Sarah L Mott, Casey F Pulliam, Michael Petronek, John B Henrich, Melissa A Fath, Jon C Houtman, Steven M Varga, Kellie L Bodeker, Aaron D Bossler, Andrew M Bellizzi, Jun Zhang, Varun Monga, Hariharasudan Mani, Marina Ivanovic, Brian J Smith, Margaret M Byrne, William Zeitler, Brett A Wagner, Garry R Buettner, Joseph J Cullen, John M Buatti, Douglas R Spitz, Bryan G Allen
PURPOSE: Platinum-based chemotherapy with or without immunotherapy is the mainstay of treatment for advanced stage non-small cell lung cancer (NSCLC) lacking a molecular driver alteration. Pre-clinical studies have reported that pharmacological ascorbate (P-AscH-) enhances NSCLC response to platinum-based therapy. We conducted a phase II clinical trial combining P-AscH- with carboplatin-paclitaxel chemotherapy. EXPERIMENTAL DESIGN: Chemotherapy naïve advanced stage NSCLC patients received 75 g ascorbate twice per week intravenously with carboplatin and paclitaxel every three weeks for four cycles...
July 2022: Redox Biology